Chair: Jonathan Barker, President, UK
Members: Craig Leonardi, Vice President & President-Elect, US Bruce Strober, Treasurer/Secretary, US Alexa Kimball, Immediate Past President, US Claudia de la Cruz, Education Chair, Chile Hervé Bachelez, Research Chair, France Christy Langan, CEO, US
Chair: Bruce Strober, US
Members: Jonathan Barker, UK Robert Holland III, US Christy Langan, US
Chair: Claudia de la Cruz, Chile
Members: Edgardo Chouela, Argentina Mahira El Sayed, Egypt Paolo Gisondi, Italy Elise Kleyn, UK Mark Lebwohl, US Mark Pittelkow, US Murlidhar Rajagopalan, India Colin Theng, Singapore Staff Liaisons: Christy Langan, Nicora Gardner, Peter van de Kerkhof
Members: Andrew Blauvelt, US Wolf-Henning Boehncke, Switzerland Arnon Cohen, Israel Chris Griffiths, UK Alice Gottlieb, US Caitriona Ryan, Ireland Lone Skov, Denmark Fernando Valenzuela, Chile Jashin Wu, US Staff Liaisons: Peter van de Kerkhof, Christy Langan
Chair: Hervé Bachelez, France
Members: April Armstrong, US André Carvalho, Brazil Michel Gilliet, Switzerland Johann Gudjonsson, US Lars Iversen, Denmark Nehal Mehta, US Jörg Prinz, Germany Ricardo Romiti, Brazil Staff Liaisons: Peter van de Kerkhof, Christy Langan
UPCOMING EVENT The mechanistic model(s) of psoriasis: Autoimmune and/or inflammatory? Wednesday, September 18, 2019 2:00 pm - 6:00 pm Bordeaux, france Register Now
IPC Psoriasis Review Newsletter IPC's bi-annual review of the latest manuscripts in the field of psoriasis. Read the latest issue
IPC's bi-annual review of the latest manuscripts in the field of psoriasis.
Psoriasis News Lilly Announces Superiority of Taltz® (ixekizumab) versus TREMFYA® (guselkumab) in Delivering Total Skin Clearance at Week 12 in Topline Results from Head-to-Head (IXORA-R) Trial in People Living with Moderate to Severe Plaque Psoriasis8/20/2019 10:08:00 AMEli Lilly and Company (NYSE: LLY) announced that Taltz® (ixekizumab) met the primary and all major secondary endpoints up to week 12 in the Phase 4 IXORA-R study, which evaluated the efficacy and safety of Taltz versus TREMFYA® (guselkumab) in people living with moderate to severe plaque psoriasis (PsO). FDA Approves OTEZLA® (apremilast) for the Treatment of Oral Ulcers Associated with Behçet’s Disease8/6/2019 11:36:00 AMCelgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has approved OTEZLA® (apremilast) 30 mg twice daily (BID) for the treatment of adult patients with oral ulcers associated with Behçet’s Disease. Updated Disease Classification System Adopted by the World Health Organization8/1/2019 7:19:00 AMOn 25 May 2019, the World Health Assembly officially adopted the eleventh revision of the International Classification of Diseases (ICD-11). The ICD-11 will come into effect on 1 January 2022. FDA Approves Samsung Bioepis' HADLIMA™ (adalimumab-bwwd)8/1/2019 7:09:00 AMSamsung Bioepis Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved HADLIMA™ (adalimumab-bwwd), a biosimilar referencing HUMIRA® (adalimumab)i , for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn’s disease, ulcerative colitis, and plaque psoriasis. Please see full indications and Boxed Warning for HADLIMA™, below. More News